EU antitrust officials charge Teva in ‘ pay-for-delay ’ deal

Antitrust regulators in the European Union charged Teva Pharmaceuticals (NYSE:TEVA) today, accusing the company of arranging an illegal deal with Cephalon to delay the sale of a cheap generic version to Cephalon’s sleep disorder drug, modafinil.
The EU competition officials have unleashed a series of fines against an array of companies in recent years over similar deals, including U.S. giant Johnson & Johnson (NYSE:JNJ).
Get the full story at our sister site, Drug Delivery Business News.
The post EU antitrust officials charge Teva in ‘pay-for-delay’ deal appeared first on MassDevice.

Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Legal News Pharmaceuticals Wall Street Beat cephalon johnsonandjohnson Teva Pharmaceuticals Source Type: news